Arcus Biosciences, Inc. (RCUS) is a publicly traded Healthcare sector company. As of May 21, 2026, RCUS trades at $23.74 with a market cap of $2.94B and a P/E ratio of -7.37. RCUS moved +4.48% today. Year to date, RCUS is +9.05%; over the trailing twelve months it is +167.64%. Its 52-week range spans $6.50 to $28.72. Analyst consensus is strong buy with an average price target of $35.89. Rallies surfaces RCUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Arcus Biosciences, Inc. (RCUS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. RCUS moved +4.48% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $23.74 |
| Market Cap | $2.94B |
| P/E Ratio | -7.37 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.72 |
| 52-Week Low | $6.50 |
| Volume | 655.90K |
| Avg Volume | 0 |
| Revenue (TTM) | $236.00M |
| Net Income | $-369.00M |
| Gross Margin | 0.00% |
10 analysts cover RCUS: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.89.